United States

AdvaMed opens 2026 award nominations ahead of The MedTech Conference in Boston

SHERIDAN, WYOMING - March 31, 2026 - Medtech companies planning 2026 leadership recognition, industry positioning, and internal talent visibility now have a defined nomination window tied to one of the sector's highest-profile annual gatherings. AdvaMed has opened nominations through April 10 for three 2026 honors: the AdvaMed Lifetime Achievement Award, the AdvaMedDx Lifetime of Leadership & Service Award, and the AdvaMed Imaging Röntgen Award. All three awards are scheduled to be presented at The MedTech Conference, set for October 18-21, 2026, in Boston.

Roche reports Phase II obesity data for petrelintide with 10.7% weight reduction at 42 weeks

Image

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

Eli Lilly Reports Phase 3b Win for Taltz and Zepbound Combination in Psoriasis Patients With Obesity

Image
Eli Lilly Reports Phase 3b Win for Taltz and Zepbound Combination in Psoriasis Patients With Obesity

SHERIDAN, WYOMING - March 13, 2026 - Eli Lilly and Company has reported positive topline results from the Phase 3b TOGETHER-PsO trial, showing that concomitant use of Taltz and Zepbound outperformed Taltz monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, the combination met the primary endpoint and all key secondary endpoints, linking deeper skin clearance with clinically meaningful weight reduction in a patient population with high disease burden. For clinicians, payers, and commercial stakeholders in immunology and obesity care, the readout is significant because it supports a more integrated treatment model for patients whose outcomes may be affected by both inflammatory disease and elevated body weight. It also extends Lilly's argument that obesity management may influence psoriasis outcomes in difficult-to-treat populations.

USOPC and Lilly Scale Athlete Recovery Support Through LA28 With a Longer-Term Care Model

Image
USOPC and Lilly Scale Athlete Recovery Support Through LA28 With a Longer-Term Care Model

SHERIDAN, WYOMING - March 13, 2026 - The United States Olympic & Paralympic Committee is extending the Team USA Athlete Recovery Program with support from Eli Lilly and Company, turning what began as a pilot into a longer-term recovery model tied to the next major Olympic and Paralympic cycles. The program will continue after the Olympic and Paralympic Winter Games Milano Cortina 2026 and through the LA28 Olympic and Paralympic Games, with a focus on athletes facing complex or extended rehabilitation needs. For sports organizations, governing bodies, and healthcare-adjacent partners, the significance lies less in sponsorship optics than in how recovery services are being structured as an operational layer of athlete support. The announcement points to a more formal approach to coordinated care, continuity, and access beyond the competition window itself.

Program expansion formalizes recovery as an ongoing support function

BioSpace hiring data points to cautious biopharma job market stabilization as 12 employers lead posting volume

Image
BioSpace hiring data points to cautious biopharma job market stabilization as 12 employers lead posting volume

SHERIDAN, WYOMING - March 04, 2026 - Hiring signals in biopharma remain mixed but usable for employers and candidates: overall job-posting activity is described as lower year over year, yet slightly higher month over month, and a late-2025 survey cited in the source suggests a meaningful share of companies expect open roles to rise in 2026. For the market, the key message is not "boom or bust," but that recruiting is still happening-especially at scale players that must protect execution capacity across late-stage development, manufacturing, commercial operations, and enabling functions. For job seekers, this translates into real pharma and biotech opportunity concentrated in employers that are still running active pipelines.

FDA escalates compounded GLP-1 enforcement with 30 telehealth warning letters and manufacturing concerns at GenoGenix

Image
FDA escalates compounded GLP-1 enforcement with 30 telehealth warning letters and manufacturing concerns at GenoGenix

SHERIDAN, WYOMING - March 04, 2026 - The U.S. Food and Drug Administration has issued 30 warning letters to telehealth companies over compounded GLP-1 products promoted on their websites, extending an enforcement campaign that previously targeted larger players in the channel. FDA officials allege some companies made false or misleading claims, implied compounded products are the same as approved medicines, or obscured product sourcing by branding drugs with their own names or trademarks. The agency also flagged manufacturing and quality concerns at one compounder, GenoGenix, including conditions that could create contamination risk and reports of multiple emergency room visits tied to a compounded product.

FDA actions hit multiple gene therapy programs as uniQure, REGENXBIO, and Sarepta updates sharpen regulatory focus

Image
FDA actions hit multiple gene therapy programs as uniQure, REGENXBIO, and Sarepta updates sharpen regulatory focus

SHERIDAN, WYOMING - March 04, 2026 - A cluster of U.S. FDA-driven developments is reshaping near-term operating plans across gene therapy developers, with uniQure disclosing a new Phase 3 requirement, REGENXBIO facing a complete response letter for its Hunter syndrome program, and Sarepta Therapeutics managing a leadership change alongside conservative 2026 sales expectations for Elevidys. The same news cycle also includes broader questions from regulatory experts about how decisions are being made inside the agency, including scrutiny around CBER leadership. For clinical, regulatory, and finance teams, the immediate takeaway is execution risk: trial design expectations, control strategy, and evidentiary standards are moving targets that can directly change timelines and cost.

EveryONE Medicines shuts down, raising questions on FDA bespoke pathway scalability for ultra-small patient populations

Image
EveryONE Medicines shuts down, raising questions on FDA bespoke pathway scalability for ultra-small patient populations

SHERIDAN, WYOMING - March 04, 2026 - EveryONE Medicines has decided to close, shortly after the FDA released draft guidance intended to help drugmakers advancing personalized genetic medicines under a bespoke framework. Reporting cited an anonymous source who said the pathway was insufficient and difficult to work with for commercializing treatments aimed at exceedingly small patient populations, while a U.S. Department of Health and Human Services spokesperson rejected the idea that the FDA framework caused the shutdown. For rare-disease operators and investors, the development spotlights a core execution constraint in individualized medicines: whether regulatory expectations can be met repeatedly and economically when each therapy is effectively a one-off product.

Moderna settles Roivant-Arbutus lipid nanoparticle dispute to cap COVID-19 IP exposure and reduce legal overhang

Image
Moderna settles Roivant–Arbutus lipid nanoparticle dispute to cap COVID-19 IP exposure and reduce legal overhang

SHERIDAN, WYOMING - March 04, 2026 - Moderna has agreed to pay up to $2.25 billion to settle its patent conflict with Roivant and Arbutus Therapeutics over alleged use of protected lipid nanoparticle technology tied to its mRNA-based COVID-19 vaccine. The settlement terms include a $950 million upfront payment and up to $1.3 billion in contingent commitments linked to the outcome of an appeal aimed at limiting Moderna's liability through certain government-contractor immunity statutes. For executives and operators, the practical impact is risk containment: the agreement reduces uncertainty around potential multi-billion-dollar exposure, clarifies near-term cash obligations, and removes a material legal distraction as Moderna manages broader portfolio and regulatory priorities.

FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

Image
FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

SHERIDAN, WYOMING - February 10, 2026 - The U.S. Food and Drug Administration entered 2026 fundamentally reshaped after a year of unprecedented leadership turnover, shifting regulatory priorities, and workforce reductions under the second Trump administration. Developments throughout 2025 altered both risk profiles and opportunity structures for companies operating in pharmaceuticals, biologics, medical devices, and regulated food markets. For executives and regulatory leaders, understanding how these changes converged is now essential for planning submissions, investments, and compliance strategies in the year ahead.